Comparing the current results to its competitors, Lyell Immunopharma Inc reported Revenue decrease in the 2 quarter 2026 year on year by -50 %, despite the revenue increase by the most of its competitors of 12.3 %, recorded in the same quarter.
Lyell Immunopharma Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 407.23 %
Lyell Immunopharma Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical industry, facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, government agencies, and public and private research institutions. Its product candidates compete with existing and emerging treatments, including approved CD19 CAR T-cell therapies, monoclonal antibodies targeting CD19, antibody-drug conjugates, bispecific antibodies, selective inhibitors of exportin 1, kinase inhibitors, cytotoxic chemotherapies, and immunotherapies. Competitors include companies developing autologous or allogeneic CAR T-cell therapies for hematologic malignancies and solid tumors. Some competitors possess substantially greater financial resources, larger research and development teams, and established marketing and sales operations.
June 26, 2024
Lyell Immunopharma, a clinical-stage T-cell reprogramming company, has released initial clinical and translational data from its Phase 1 trial of LYL797. This first-generation reprogrammed ROR1 CAR T-cell product candidate, enhanced with proprietary anti-exhaustion technology, shows promising results in patients with triple-negative breast cancer (TNBC). The trial demonstrates dose-dependent antitumor clinical activity, along with the ability of LYL797 CAR T cells to proliferate, infiltrate tumors, and effectively target cancer cells in patients with relapsed/refractory disease.Clinical Trial Results:The initial dataset primarily includes patients with TNBC, showcasing encouraging outcomes. At the 150 x 10^6...
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
Senti Biosciences Inc is a biotechnology company that develops and commercializes novel therapeutics using synthetic biology and gene editing technology.
Sensei Biotherapeutics Inc is a biotechnology company that focuses on developing personalized and targeted cancer therapies. They employ a unique approach called ImmunoPhage, which utilizes bacteriophages to specifically target tumor antigens and stimulate an immune response. Their business model revolves around conducting research and clinical trials to bring innovative cancer treatment options to market.
Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.
Sources:
Lyell Immunopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lyell Immunopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
